Indaptus Therapeutics Inc
INDP7.310USD
+0.010+0.14%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
117.21MMarket Cap
LossP/E TTM
More Details of Indaptus Therapeutics Inc Company
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Company Info
Ticker SymbolINDP
Company nameIndaptus Therapeutics Inc
IPO dateSep 07, 2012
CEOMr. Jeffrey A. Meckler
Number of employees7
Security typeOrdinary Share
Fiscal year-endSep 07
Address3 Columbus Circle
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10019
Phone16464272727
Websitehttps://indaptusrx.com/
Ticker SymbolINDP
IPO dateSep 07, 2012
CEOMr. Jeffrey A. Meckler
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Chief Executive Officer, Director
Chief Executive Officer, Director
13.31K
+83.75%
Mr. Anthony J. Maddaluna
Mr. Anthony J. Maddaluna
Independent Director
Independent Director
24.00
--
Mr. Walt Addison Linscott, Esq.
Mr. Walt Addison Linscott, Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Mark J. Gilbert, M.D.
Dr. Mark J. Gilbert, M.D.
Independent Director
Independent Director
--
--
Mr. William Bradley (Brad) Hayes
Mr. William Bradley (Brad) Hayes
Independent Director
Independent Director
--
--
Dr. Robert E. Martell, M.D., Ph.D.
Dr. Robert E. Martell, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Roger J. Pomerantz, M.D.
Dr. Roger J. Pomerantz, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Michael J. Newman, Ph.D.
Dr. Michael J. Newman, Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
--
--
Ms. Hila Karah
Ms. Hila Karah
Independent Director
Independent Director
--
--
Dr. Roger J. Waltzman, M.D.
Dr. Roger J. Waltzman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Chief Executive Officer, Director
Chief Executive Officer, Director
13.31K
+83.75%
Mr. Anthony J. Maddaluna
Mr. Anthony J. Maddaluna
Independent Director
Independent Director
24.00
--
Mr. Walt Addison Linscott, Esq.
Mr. Walt Addison Linscott, Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Mark J. Gilbert, M.D.
Dr. Mark J. Gilbert, M.D.
Independent Director
Independent Director
--
--
Mr. William Bradley (Brad) Hayes
Mr. William Bradley (Brad) Hayes
Independent Director
Independent Director
--
--
Dr. Robert E. Martell, M.D., Ph.D.
Dr. Robert E. Martell, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yorkville Advisors Global, LP.
4.51%
Newman (Michael James)
4.37%
Mollick (Thomas)
3.87%
Anderson (Glen R)
3.80%
Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014
3.42%
Other
80.03%
Shareholders
Shareholders
Proportion
Yorkville Advisors Global, LP.
4.51%
Newman (Michael James)
4.37%
Mollick (Thomas)
3.87%
Anderson (Glen R)
3.80%
Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014
3.42%
Other
80.03%
Shareholder Types
Shareholders
Proportion
Individual Investor
37.93%
Investment Advisor/Hedge Fund
9.81%
Investment Advisor
2.96%
Hedge Fund
0.20%
Research Firm
0.11%
Other
48.99%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
39
286.05K
26.20%
+51.09K
2025Q1
41
314.45K
54.91%
+74.11K
2024Q4
38
3.40M
36.41%
+124.70K
2024Q3
37
3.32M
37.71%
+124.67K
2024Q2
39
3.23M
38.10%
+60.54K
2024Q1
41
3.22M
38.25%
+17.47K
2023Q4
41
3.24M
38.53%
+25.69K
2023Q3
46
3.21M
38.17%
-416.96K
2023Q2
49
3.81M
45.86%
-640.11K
2023Q1
55
3.81M
45.81%
-721.88K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Yorkville Advisors Global, LP.
50.39K
8.8%
+50.39K
--
Feb 13, 2025
Newman (Michael James)
48.87K
8.53%
--
--
Jun 16, 2025
Mollick (Thomas)
43.32K
7.56%
--
--
Jun 16, 2025
Anderson (Glen R)
42.51K
7.42%
--
--
Jun 16, 2025
Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014
38.26K
6.68%
--
--
Jun 16, 2025
Shimoni (Yehuda)
30.90K
5.4%
--
--
Jun 16, 2025
Meckler (Jeffrey A)
7.25K
1.27%
--
--
Jun 16, 2025
The Vanguard Group, Inc.
9.15K
1.6%
--
--
Mar 31, 2025
The Investment House LLC
4.60K
0.8%
+1.02K
+28.62%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.46K
0.78%
+1.53K
+52.17%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 26, 2021
Merger
4<1
Jul 26, 2021
Merger
4<1
Jul 26, 2021
Merger
4<1
Jul 26, 2021
Merger
4<1
Oct 29, 2020
Merger
20<1
Oct 29, 2020
Merger
20<1
Date
Type
Ratio
Jul 26, 2021
Merger
4<1
Jul 26, 2021
Merger
4<1
Jul 26, 2021
Merger
4<1
Jul 26, 2021
Merger
4<1
Oct 29, 2020
Merger
20<1
Oct 29, 2020
Merger
20<1
Oct 29, 2020
Merger
20<1
Oct 29, 2020
Merger
20<1
